Supernus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents…
INTO ONOKUYITHATHA KWELI NQAKU:
- The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents….
- Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.
- announced that the U.